...
首页> 外文期刊>Expert opinion on therapeutic targets >Targeting glia for bone cancer pain
【24h】

Targeting glia for bone cancer pain

机译:针对神经胶质瘤的骨痛

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Bone cancer pain (BCP) remains to be a clinical challenge with limited pharmaceutical interventions. Therefore, novel therapeutic targets for the management of BCP are in desperate need. Recently, a growing body of evidence has suggested that glial cells may play a pivotal role in the pathogenesis of BCP.Areas covered: This review summarizes the recent progress in the understanding of glia in BCP and reveals the potential therapeutic targets in glia for BCP treatment.Expert opinion: Pharmacological interventions inhibiting the activation of glial cells, suppressing glia-derived proinflammatory cytokines, cell surface receptors, and the intracellular signaling pathways may be beneficial for the pain management of advanced cancer patients. However, these pharmacological interventions should not disrupt the normal function of glia cells since they play a vital supportive and protective role in the central nervous system.
机译:简介:有限的药物干预仍然是骨癌疼痛(BCP)的临床挑战。因此,迫切需要用于BCP管理的新型治疗靶标。最近,越来越多的证据表明神经胶质细胞可能在BCP的发病机理中起着关键作用。研究领域:本综述总结了对BCP的神经胶质认识的最新进展,并揭示了神经胶质在BCP治疗中的潜在治疗靶点专家意见:药理学干预可抑制神经胶质细胞的活化,抑制胶质细胞来源的促炎细胞因子,细胞表面受体和细胞内信号传导途径,可能有助于晚期癌症患者的疼痛控制。但是,这些药理干预措施不应破坏神经胶质细胞的正常功能,因为它们在中枢神经系统中起着至关重要的支持和保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号